Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical outcome measures for progressive MS trials.

Daniel Ontaneda1, Jeffrey A Cohen1, Maria Pia Amato2

  • 1Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 19, 2017
PubMed
Summary

Finding effective treatments for progressive multiple sclerosis (MS) is crucial. This review examines clinical outcome measures, including novel composites and patient-reported outcomes, to assess new MS therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complex Deep Neural Networks for Denoising Ultra-Fast Submillimeter T2*-weighted Imaging and Quantitative Susceptibility Mapping.

European journal of radiology artificial intelligence·2026
Same author

Multiple sclerosis as an asynchronous neuroinflammatory system.

Frontiers in immunology·2026
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.

Journal of neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Area of Science:

  • Neurology
  • Clinical Trials
  • Neuroimmunology

Background:

  • Progressive multiple sclerosis (MS) lacks effective treatments, representing a significant unmet need.
  • Advancing understanding of MS pathogenesis drives the development of novel therapeutic targets.
  • Robust clinical outcome measures are essential for demonstrating treatment efficacy to stakeholders.

Purpose of the Study:

  • To review and discuss current and novel clinical outcome measures for progressive MS clinical trials.
  • To evaluate the suitability of cognitive outcomes, screening tests, and patient-reported outcomes in MS research.
  • To foster consensus on outcome measures and guide future research directions in progressive MS treatment.

Main Methods:

  • Comprehensive literature review of clinical outcome measures in multiple sclerosis (MS) trials.
Keywords:
Progressive multiple sclerosisclinical trialscognitionoutcome measurespatient-reported outcomes

Related Experiment Videos

  • Analysis of established scales like the Expanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC).
  • Evaluation of emerging composite measures, cognitive assessments, and patient-reported outcomes (PROs).

    • Main Results:

    • The review synthesizes information on various outcome measures used in progressive MS clinical trials.
    • It highlights the strengths and limitations of traditional scales and the growing role of novel composite and patient-reported outcomes.
    • Cognitive outcomes and screening tests are discussed for their utility in assessing treatment effects.

    Conclusions:

    • Standardized and novel outcome measures, including PROs, are vital for evaluating progressive MS treatments.
    • Consensus on appropriate outcome measures will accelerate the development and approval of new therapies.
    • Future research should focus on refining and validating these measures to better reflect treatment benefits for individuals with MS.